Daniel Petersen, MD
Sleep Medicine · Fitchburg, WINPI 1578049763
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Inspire Medical Systems, Inc. accounts for 65.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $696 and has fallen 59.2% since, to $284 in 2025.
Across 13 payments — averaging $98.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$830
- Jazz Pharmaceuticals Inc.$235
- Novartis$147
- Harmony Biosciences LLC$30
- Otsuka Pharmaceutical Development & Commercialization, Inc.$21
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$13
What the payments were for
- Consulting fees$15012%
- Travel & lodging$65651%
- Food & beverage$38530%
- Education$857%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 6 | $830 |
| Jazz Pharmaceuticals Inc. | 2 | $235 |
| Novartis | 2 | $147 |
| Harmony Biosciences LLC | 1 | $30 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,276 in reported general payments places this provider in the 85th percentile of 31 sleep medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Modafinil | 27 | $2,115 |
| Dextroamphetamine Sulfate | 18 | $1,289 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 20 | $438 |
| Doxepin Hcl | 13 | $426 |
| Ropinirole Hcl | 20 | $415 |
| Fluticasone Propionate | 22 | $394 |
| Gabapentin | 32 | $382 |
| Zolpidem Tartrate | 61 | $378 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 12 | $157 |
| Clonazepam | 13 | $63 |
| Trazodone Hcl | 16 | $41 |
Paid to pharmacies, not to this prescriber.
Other sleep medicine in Fitchburg
- Scott JohnsonFitchburg$146
- Harrison GimbelFitchburg$16
- Jacalyn NelsonFitchburg$0
- Joseph CrisalliFitchburg$0
- Ewa AlexanderFitchburg$0
- David PlanteMadison$190K
- Brittany MeyerDelafield$3K
- Ivy Andersenla Crosse$2K
- Ethan EmmonsGreen Bay$2K
- Deane FransoGreen Bay$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.